| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Dates (the fruit of Phoenix dactylifera) have been increasingly studied for their potential anticancer and cancer-preventive properties, mainly due to their rich phytochemical content and strong antioxidant activity. Dates contain a broad spectrum of bioactive compounds linked to cancer prevention: -Phenolic acids – e.g., ferulic acid, gallic acid, caffeic acid, and p-coumaric acid -Flavonoids – e.g., quercetin, luteolin, apigenin -Carotenoids – e.g., β-carotene, lutein -Tannins, saponins, and sterols -Dietary fiber and polysaccharides These compounds have antioxidant, anti-inflammatory, and antiproliferative effects. Date fiber and polyphenols foster beneficial gut bacteria (e.g., Bifidobacterium, Lactobacillus) that produce short-chain fatty acids (SCFAs), which protect the colon and may lower colon cancer risk. Date Fruit Extract — a non-standardized botanical extract prepared from the edible fruit pulp of Phoenix dactylifera L., including cultivars such as Ajwa, Medjool, Hallawi, Sukkari, and others. It is classified as a complex food-derived phytochemical mixture rather than a single defined drug or active pharmaceutical ingredient. The standard abbreviation is DFE. Principal constituents vary substantially with cultivar, ripeness, processing, and extraction solvent, but commonly include phenolic acids such as gallic, ferulic, caffeic, protocatechuic, and p-coumaric acids; flavonoids such as quercetin, luteolin, apigenin, catechin, and epicatechin derivatives; carotenoids; condensed tannins; polysaccharides; and dietary fiber. Date fruit, date seed, leaf, pollen, and nanoparticle preparations are compositionally distinct and should not be treated as interchangeable with fruit-pulp extract. Primary mechanisms (ranked):
Bioavailability / PK relevance: No clinically validated pharmacokinetic profile exists for DFE as a standardized anticancer agent. Its polyphenols undergo incomplete intestinal absorption, extensive phase-II conjugation, microbial metabolism, and rapid systemic clearance. Consequently, circulating concentrations of individual parent compounds are generally much lower than concentrations used for direct cancer-cell cytotoxicity. Local gastrointestinal exposure and microbial metabolites may be more biologically relevant than systemic exposure after ordinary date consumption. In-vitro vs systemic exposure relevance: Most antiproliferative studies use crude solvent fractions at tens to hundreds of micrograms per millilitre. These concentrations cannot be directly equated with plasma exposure after eating dates or taking an unstandardized extract. Extract-specific cytotoxic effects may reflect concentrated mixtures, solvent-selective enrichment, or interactions among multiple constituents. Common in-vitro exposures probably exceed achievable systemic concentrations from dietary intake. Clinical evidence status: Preclinical. Evidence consists primarily of cell-culture studies, limited animal experiments, compositional studies, and small human dietary studies evaluating metabolic, inflammatory, or gastrointestinal outcomes. No randomized controlled oncology trial has established DFE as a cancer treatment, adjunctive anticancer therapy, radiosensitizer, or chemotherapy sensitizer. Date fruit and date-derived extracts are not approved by Health Canada, the FDA, or the EMA as anticancer drugs. Safety and deployment: Whole dates are conventional foods and are generally well tolerated, but they contain substantial carbohydrate and sugar and may require portion control in people with impaired glycemic regulation. Extracts may differ markedly from the food in concentration, solvent residues, composition, and contaminant risk. Clinical interaction data with chemotherapy, anticoagulants, endocrine therapies, or targeted agents are inadequate. DFE should not be assumed to protect normal tissue selectively or improve anticancer treatment efficacy without direct combination studies. Date Fruit Extract Mechanistic Profile
TSF: P: 0–30 min R: 30 min–3 hr G: >3 hr |
| Source: |
| Type: |
| Neuroprotective refers to the ability of a substance, intervention, or strategy to preserve the structure and function of nerve cells (neurons) against injury or degeneration. -While cancer and neurodegenerative processes might seem distinct, there is significant overlap in terms of treatment-related neurotoxicity, shared molecular mechanisms, and the potential for therapies that provide neuroprotection during cancer treatment. |
| 6663- | DFE, | Nutraceuticals of Phoenix dactylifera L.: Physicochemistry, Nutritional Value and Therapeutic Potential |
| - | Review, | Nor, | NA | - | Review, | AD, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:371 Target#:1105 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid